- Transthyretin amyloid cardiomyopathy is a life-threatening, progressive disease that is often underdiagnosed and misdiagnosed
- Certain clinical scenarios have been identified that now warrants screening for transthyretin amyloid cardiomyopathy
- Once transthyretin cardiomyopathy suspected definitive diagnosis can usually be achieved noninvasively
- Accurate, early diagnosis of transthyretin cardiomyopathy ischemic to enabling appropriate patient care
screening for transthyretinamyloid cardiomyopathy in everyday practice, published in JACC HF failure, July 2019
Journal of the American College of cardiology state-of-the-art review:
transthyretin amyloid cardiomyopathy
The following Webinar from the European Society of Cardiology ( ESC) which gives a good overview about the diagnosis and treatment various forms of cardiac amyloidosis, presenting several case reports
